Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cephalosporins in clinical development.

Malcolm G P Page1

  • 1Basilea Pharmaceutica AG, Postfach, CH-4005 Basel, Switzerland. malcolm.page@basilea.com

Expert Opinion on Investigational Drugs
|July 23, 2004
PubMed
Summary

New cephalosporins show potent activity against multi-drug resistant bacteria, including methicillin-resistant staphylococci. These broad-spectrum antibiotics offer a promising solution for treating challenging hospital infections caused by resistant organisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A unified annotation scheme for class D β-lactamases.

Antimicrobial agents and chemotherapy·2025
Same author

Siderophore cephalosporins.

EcoSal Plus·2025
Same author

Revitalizing antibiotic discovery and development through in vitro modelling of in-patient conditions.

Nature microbiology·2024
Same author

Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors.

Nature chemistry·2021
Same author

Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.

Antimicrobial agents and chemotherapy·2020
Same author

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from <i>Escherichia coli</i>.

Biomolecules·2020

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Increasing bacterial resistance to antibiotics necessitates novel therapeutic agents.
  • Cephalosporins have historically evolved to overcome drug resistance, particularly beta-lactamase activity.
  • Gram-negative pathogens and staphylococci are key targets for antibiotic development.

Purpose of the Study:

  • To evaluate new cephalosporin agents for activity against multi-drug resistant bacteria.
  • To assess the potential of these agents in treating hospital-acquired infections.
  • To identify novel cephalosporins with broad-spectrum activity.

Main Methods:

  • Clinical development of new cephalosporin candidates.
  • Assessment of antibacterial spectrum and potency.
  • Comparison with existing third- and fourth-generation cephalosporins.

Main Results:

  • New cephalosporins demonstrate potent activity against multi-resistant Gram-positive bacteria, including methicillin-resistant staphylococci and penicillin-resistant pneumococci.
  • Agents BAL-5788 and S-3578 exhibit Gram-negative activity comparable to current advanced cephalosporins.
  • These novel compounds show potential as broad-spectrum agents.

Conclusions:

  • The development of new cephalosporins is crucial for combating rising antibiotic resistance.
  • BAL-5788 and S-3578 represent promising candidates for treating infections caused by multi-drug resistant organisms.
  • These agents could be valuable in hospital settings with a high prevalence of methicillin-resistant staphylococci.

Related Experiment Videos